This site is intended only for healthcare professionals resident in the Republic of Ireland
Find the information you need to support your RA patient here.
Find the information you need to support your PsA patient here.
Find the information you need to support your UC patient here.
If you are new to XELJANZ, learn more about XELJANZ dosing here.
Click here for an overview of the safety profile of XELJANZ.
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
JAK=Janus kinase; RA=rheumatoid arthritis; UC=ulcerative colitis; PsA=psoriatic arthritis; AS=ankylosing spondylitis; JIA= juvenile idiopathic arthritis
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023